NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRYNGOLZA is an antisense oligonucleotide (olezarsen sodium) administered via subcutaneous autoinjector approved by the FDA on December 19, 2024. The drug represents Ionis Pharmaceuticals' entry into a specialized therapeutic area with a novel RNA-based mechanism. Specific indications and clinical efficacy data are not detailed in current public materials but reflect the company's pipeline maturation in oligonucleotide therapeutics.
Growth7.5 years to LOE
Early-stage growth phase with zero documented competitive pressure indicates a niche positioning; commercial teams should expect build-out in specialty sales, patient services, and market access infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRYNGOLZA at launch offers exposure to Ionis' pioneering antisense platform and a rare orphan/specialty product with zero current competition. Roles are concentrated in specialty sales, patient support, and market access rather than broad primary care, creating distinct expertise in RNA therapeutics, reimbursement strategy, and niche patient management.
Brand Manager
Worked on TRYNGOLZA (AUTOINJECTOR) at Ionis Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.